# Galapagos NV (GLPG) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GLPG
## Company Profile
- Ticker: GLPG
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Belgium
- Tags: Immunology
## Stock Data
- Close: 27.73 USD
- Market cap: 1827325778.83 USD
- Last updated: 2026-05-07
## Business Overview
Galapagos is a biotechnology company with a long history in immunology and inflammatory disease, and it has also redefined itself around partnership and pipeline strategy. Its story is shaped by platform science, corporate evolution, and a global footprint.
## Why The Stock Is Moving

Current closing-price context is not available for GLPG.

## Geographic Base

Galapagos is headquartered in Belgium and listed on NASDAQ. It sits in global specialty biotechnology.

## Business Model

The company depends on pipeline progress, partnership strategy, and the ability to convert its scientific base into durable value. Investors watch clinical updates, business development, and portfolio direction.

## Landscape Position

Galapagos occupies a global immunology-biotech niche. The stock is driven by whether the company can keep its innovation engine relevant after strategic shifts.

## Future Catalysts

- Galapagos’s catalysts are oncology and cell-therapy repositioning, plus any update that clarifies how much value remains in the post-reshape platform. The market will care more about strategic direction than about broad pipeline optionality.

## Recent News
- 2016-09-26 00:20 EST — [Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease](https://biopharmsignal.com/news/GLPG/endoscopic-improvements-with-filgotinib-are-consistent-with-clinical-remission-r-6e24c2fe) — Source: Galapagos NV
- 2016-04-28 20:13 EST — [Galapagos kick-starts 2016 with Q1 cash position of EU988 M](https://biopharmsignal.com/news/GLPG/galapagos-kick-starts-2016-with-q1-cash-position-of-eu988-m-2c349187) — Source: Galapagos NV
- 2016-04-03 20:29 EST — [Galapagos increases share capital through warrant exercises](https://biopharmsignal.com/news/GLPG/galapagos-increases-share-capital-through-warrant-exercises-b5aa223d) — Source: Galapagos NV
- 2016-03-25 21:06 EST — [Publication of the annual report and invitation to the Annual and Extraordinary Shareholders' Meetings](https://biopharmsignal.com/news/GLPG/publication-of-the-annual-report-and-invitation-to-the-annual-and-extraordinary--b139be11) — Source: Galapagos NV
- 2016-01-19 22:02 EST — [Galapagos and Gilead complete closing of their global collaboration for filgotinib](https://biopharmsignal.com/news/GLPG/galapagos-and-gilead-complete-closing-of-their-global-collaboration-for-filgotin-de7bd867) — Source: Galapagos NV